Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

(2012) W. C. Reinhold et al.   CANCER RESEARCH

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Cell lines battle cancer

(2012) John N. Weinstein   NATURE

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Exon Array Analyses across the NCI-60 Reveal Potential Regulation of TOP1 by Transcription Pausing at Guanosine Quartets in the First Intron

(2010) W. C. Reinhold et al.   CANCER RESEARCH

mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities

(2010) H. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

(2010) S. L. Holbeck et al.   MOLECULAR CANCER THERAPEUTICS

Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets

(2010) Kosuke Yoshihara et al.   PLoS One

CellMiner: a relational database and query tool for the NCI-60 cancer cell lines

(2009) Uma T Shankavaram et al.   BMC GENOMICS

Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence

(2009) Olivia Bustos et al.   GENE

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET